Skip to main content

Table 2 Longitudinal changes in ARR and EDSS in naïve and switcher patients during V1-V2 tested using the WM test

From: Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients

Pre vs Post comparison

Previous 24 months

V1-V2

p

Switchers, n = 130

 ARR

0.5 (0.0–0.5)

0.0 (0.0–0.0)

0.022

Naïve, n = 64

 ARR

0.5 (0.5–1.0)

0.0 (0.0–0.0)

2.90E-10

 

V1

V2

p

Switchers, n = 130

 EDSS

2.5 (2.0–3.8)

2.5 (1.5–4.0)

0.852

Naïve, n = 64

 EDSS

2.0 (1.5–2.5)

1.5 (1.0–2.5)

0.003

  1. ARR Annualized relapse rate, EDSS Expanded disability status scale, V Visit